regulates genes

Reglagene develops new medicines that attack cancers weaknesses

Too often cancer survivors hear the life-shattering words, Your cancer is back.” Cancer changes itself to nullify even the most effective treatments. Therapy resistance is the greatest challenge cancer patients face today. At Reglagene, we develop medicines that attack the root causes of therapy resistance to keep cancer patients responsive to treatment. 

 

When confronted with therapy, cancer is in a fight for its life. Cancer responds with genetic modifications that alter gene expression profiles to create a survival benefit that defeats the therapy. That’s when cancer comes roaring back. But these genetic changes are also cancer’s weaknesses, because they are essential for its survival. What patients need is a way to effectively reverse cancer’s genetic changes to enable treatments to work better and longer.

 

Reglagene’s mission is to discover and develop low-cost and noninvasive therapeutic solutions that regain control of genes exploited by cancer. Our platform technology targets unusual DNA structures that are natural controllers of gene expression rate. These structures present topological features that enable selective gene control and the minimization of unwanted side effects.

SAFETY FIRST 

 

Unlike gene-editing technologies, Reglagene’s approach results in therapeutic effects that last only as long as the medicine is on board. This means that once the treatment is ended and the cancer has been eliminated, the body will return to its natural, healthy state. This approach also provides an added measure of safety. If adverse effects are observed in the patient, treatment can be stopped.

VARIABLE GENE EXPRESSION CONTROL

Reglagene’s technology is not a binary on or off switch for gene expression. Depending on the amount of medicine on board and the desired effect, gene expression can be dialed up or down based on the therapeutic need.

SELECTIVE CAPABILITIES 

 

Reglagene’s technology for creating new medicines leverages unique DNA structural features to identify medicines that act on specific genes to create targeted therapies based on the genetic makeup of a patient’s tumor.

MEDICINES FOR A GLOBAL MARKET 

We access the advantages of what are known as small-molecule medicines:  variable routes of administration (including oral and intravenous), lowest manufacturing costs relative to other therapeutic modalities, and well-traveled development and regulatory pathways.

GENE REGULATION TECHNOLOGY

NEWS & UPDATES

CONTACT US

1703 E Mabel St  |  Tucson,  AZ  85721  |   USA

OFFICE

1703 E Mabel St
Tucson, AZ 85721
USA

www.reglagene.com  |  ©2020 by Reglagene Holding, Inc.